Neuraltus scores $17M to treat degenerative brain disease

Neuraltus Pharmaceuticals, developer of drugs used to treat degenerative neurological diseases, brought in $17 million in a first round of funding from Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners. The Menlo Park, Calif.-based company says it’s currently working on therapies for conditions ranging from Lou Gehrig’s Disease to Parkinson’s Disease.

The money should be enough to push drugs for both these diseases through the first two phases of clinical trials, Neuraltus says.

Next Story: Barosense looks to raise $30M to market obesity device
Previous Story: Tesla unveils electric sedan with sky-high hopes